Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957733 | 0.81 | — | — | |
| Catechol SCHEMBL7374101 | 0.81 | MAPT (0.39) | LMNAMAPTTDP1KDM4ENPC1 | |
| Catechol SCHEMBL4962173 | 0.76 | CA2 (0.42) | LMNAMAPTTDP1KDM4ENPC1 | |
| SCHEMBL2971779 | 0.72 | GAA (0.69) | LMNAMAPTCA2HPGDSMN1; SMN2 | |
| SCHEMBL844313 | 0.69 | — | — | |
| Catechol SCHEMBL29489384 | 0.67 | ALDH1A1 (0.59) | LMNAMAPTTDP1KDM4ENPC1 | |
| SCHEMBL9121365 | 0.65 | GAA (0.64) | LMNAMAPTNPC1ALDH1A1CA2 | |
| SCHEMBL8609239 | 0.65 | — | — | |
| Catechol SCHEMBL28985421 | 0.65 | ALDH1A1 (0.77) | LMNAMAPTTDP1KDM4ENPC1 | |
| Catechol SCHEMBL132726 | 0.65 | ALDH1A1 (0.77) | LMNAMAPTTDP1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160000857-A1 | Method of Regulating Glucose Metabolism, and Reagents Related Thereto | NATIONAL INSTITUTES OF HEALTH | 2016-01-07 | — | — | US | disclosed |
| US-9044424-B2 | Methods of regulating glucose metabolism, and reagents related thereto | 1149336 ONTARIO, INC. (CA) | 2015-06-02 | — | — | US | disclosed |
| EP-2823812-A1 | Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes | TRUSTEES OF TUFTS COLLEGE (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2769715-A2 | Methods for treating autoimmune disorders, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20140178472-A1 | Methods of Regulating Glucose Metabolism, and Reagents Related Thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2014-06-26 | — | — | US | disclosed |
| US-8513190-B2 | Method of regulating glucose metabolism, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2583675-A1 | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism | TRUSTEES OF TUFTS COLLEGE (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2574336-A1 | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism | TRUSTEES OF TUFTS COLLEGE (US) | 2013-04-03 | — | — | EP | disclosed |
| US-8410053-B2 | Methods for treating autoimmune disorders, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2013-04-02 | — | — | US | disclosed |
| US-8318669-B2 | Method of regulating glucose metabolism, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2012-11-27 | — | — | US | disclosed |
| US-5242904-A | Anticoagulant, antiinflammatory | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| WO-1993008259-A2 | INHIBITORS OF DIPEPTIDYL-AMINOPEPTIDASE TYPE IV | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0528858-A4 | INHIBITORS OF DIPEPTIDYL-AMINOPEPTIDASE TYPE IV | — | 1993-04-28 | — | — | EP | disclosed |
| EP-0293881-B1 | PEPTIDE BORONIC ACID INHIBITORS OF TRYPSIN-LIKE PROTEASES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-10 | — | — | EP | disclosed |
| EP-0528858-A1 | INHIBITORS OF DIPEPTIDYL-AMINOPEPTIDASE TYPE IV. | NEW ENGLAND MEDICAL CENTER INC (US) | 1993-03-03 | — | — | EP | disclosed |
| US-5187157-A | Anticoagulant, antiinflammatory agents | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
| WO-1991016339-A1 | INHIBITORS OF DIPEPTIDYL-AMINOPEPTIDASE TYPE IV | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1991-10-31 | — | — | WO | disclosed |
| US-4935493-A | Protease inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-06-19 | — | — | US | disclosed |
| WO-1989003223-A1 | PROTEASE INHIBITORS | BACHOVCHIN WILLIAM W (US) | 1989-04-20 | — | — | WO | disclosed |
| EP-0293881-A2 | Peptide boronic acid inhibitors of trypsin-like proteases | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178472-A1 | Methods of Regulating Glucose Metabolism, and Reagents Related Thereto | LPL, LIPC, GCKR | LMNA 976/4885MAPT 2368/4885TDP1 3699/4885 |
| US-20160000857-A1 | Method of Regulating Glucose Metabolism, and Reagents Related Thereto | LPL, LIPC, LIPE | LMNA 1008/4885MAPT 2652/4885TDP1 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.